SCHEMBL4737537

SCHEMBL4737537

Oc1cccc(Nc2nccc(-c3cccc(O)c3)n2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.67
PLK1 P53350 5/20 0.66
CDK4 P11802 3/20 0.62
CDK2 P24941 3/20 0.62
CAMK2D Q13557 1/20 0.59
KDR P35968 1/20 0.58
PTK2 Q05397 1/20 0.58
AURKB Q96GD4 1/20 0.58
ABL1 P00519 5/20 0.56
BCR P11274 5/20 0.56
PRKCA P17252 2/20 0.56
SRC P12931 2/20 0.56
PRKCD Q05655 1/20 0.56
EGFR P00533 1/20 0.56
PRKACA P17612 1/20 0.56
PRKACG P22612 1/20 0.56
PRKACB P22694 1/20 0.56
MAPK8 P45983 2/20 0.56
PIK3CG P48736 2/20 0.56
GSK3B P49841 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27116530 0.93 PLK1 (0.68) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL4905928 0.91 PLK1 (0.72) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL2945644 0.91 PLK1 (0.79) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL14530851 0.91 PLK1 (0.75) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL4732256 0.91 PLK1 (0.59) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL14023402 0.91 PLK1 (0.59) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL4786087 0.90 PLK1 (0.78) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL4736547 0.89 ABL1 (0.63) SYKPLK1ABL1BCRPRKCA
SCHEMBL4735323 0.88 PLK1 (0.57) SYKPLK1CDK4CDK2CAMK2D
SCHEMBL4786174 0.88 PLK1 (0.57) SYKPLK1CDK4CDK2CAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 US claimed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 WO claimed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US claimed
JP-2007500179-A 2007-01-11 JP claimed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 CN claimed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 EP claimed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO claimed
CN-106795173-B The derivative of big ring N- aryl -2- amino -4- aryl-pyrimidin polyethers as FTL3 and JAK inhibitor 皮埃尔法布雷医药公司 2019-05-31 CN disclosed
EP-3189060-B1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PF MEDICAMENT (FR) 2018-06-20 EP disclosed
EP-3189060-B1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PF MEDICAMENT (FR) 2018-06-20 EP disclosed
US-20170281622-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PIERRE FABRE MEDICAMENT (FR) 2017-10-05 US disclosed
US-20170281622-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PIERRE FABRE MEDICAMENT (FR) 2017-10-05 US disclosed
US-20170281622-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK PIERRE FABRE MEDICAMENT (FR) 2017-10-05 US disclosed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 WO disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 US disclosed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 CN disclosed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 EP disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors GRK3, NCOR1, GRM3 SYK 1865/4885PLK1 1603/4885CDK4 642/4885
US-20080153822-A1 Methods of treating pain OPRL1, ACHE, OPRK1 SYK 1957/4885PLK1 3544/4885CDK4 4152/4885
US-20170281622-A1 DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK JAK2, JAK3, JAK1 SYK 491/4885PLK1 41/4885CDK4 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.